Talk:Microdosing: Difference between revisions

'''Microdosing''' (also known as '''psychedelic microdosing''') is the practice of using sub-threshold doses of a psychedelic substance in an attempt to produce a therapeutic or [[nootropic]] effect. Microdosing has been claimed by some to have a wide range of benefits including enhancing productivity, treating symptoms of psychological disorders such as clinical depression and adult ADD/ADHD, boosting creativity and problem-solving abilities, as well as increase spiritual awareness. There is currently no clinical evidence to support these claims, however a number of small scale studies have shown positive outcomes. In 2020 a study by the Beckley Foundation found that a 20 microgram dose of LSD significantly reduced pain perception when compared to a placebo, with results comparable to those observed after administration of opioids.<ref>{{Cite web|url=https://www.leafie.co.uk/psychedelics/5-things-you-need-to-know-about-microdosing/|title=5 things you need to know about microdosing|website=leafie|access-date=16 September 2021}}</ref>

While the practice has its origins with [[LSD]], it is in theory possible to microdose with any [[psychedelic]] substance. There are a growing body of reports of microdosing [[psilocybin mushrooms]], or psychedelic [[research chemicals]], particularly [[LSD]] analogs such as [[ALD-52]], [[1P-LSD]], [[AL-LAD]] and [[ETH-LAD]].  

Microdoses range from about one tenth of an active dose. A microdose of LSD is generally considered to be between 5-15 micrograms. This can be measured accurately using [[volumetric dosing]] techniques. A microdose of psilocybin mushrooms is harder to determine due to the variations in potency between species and batches; it is generally advised to start with no more than .25g.